lncTAC Bio

lncTAC Bio is a clinical-stage biotechnology company headquartered in Chengdu, China, specializing in the development of innovative nucleic acid therapeutics based on long non-coding RNA (lncRNA). Founded in 2021 by pioneer lncRNA researcher Professor Xu Song, the company leverages its proprietary lncTAC® (lncRNA-based Targeting Chimera) and UNAST® platforms to address traditionally "undruggable" targets and overcome challenges in nucleic acid drug stability and extrahepatic delivery. lncTAC Bio's pipeline spans dermatology, oncology, cardiovascular, and respiratory diseases, with its lead candidate, LT-010, a transdermal small nucleic acid targeting the androgen receptor for androgenetic alopecia, currently in Phase 1 clinical development. The company operates on a dual-engine model of independent R&D and strategic out-licensing partnerships, including a residency in the Bayer Co.Lab incubator.